Skip to main content

Anticoagulant

5
Pipeline Programs
4
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Blau Farmaceutica
Blau FarmaceuticaBrazil - São Paulo
2 programs
2
HeparinPhase 11 trial
HeparinPhase 11 trial
Active Trials
NCT05788900Unknown68Est. Sep 2023
NCT05788913Unknown68Est. Sep 2023
Chong Kun Dang Pharmaceutical
2 programs
2
LixianaPhase 11 trial
LixianaPhase 11 trial
Active Trials
NCT04673695Unknown50Est. Jan 2021
NCT04867200Unknown60Est. Jun 2021
WD Pharmaceutical
WD PharmaceuticalChina - Shanghai
1 program
1
WD-1602Phase 11 trial
Active Trials
NCT04592822Unknown20Est. Dec 2021
Roche
RocheSTAVANGER NORWAY, Norway
1 program
acenocoumarolN/A1 trial
Active Trials
NCT03154489Completed204Est. Sep 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Blau FarmaceuticaHeparin
Blau FarmaceuticaHeparin
Chong Kun Dang PharmaceuticalLixiana
WD PharmaceuticalWD-1602
Chong Kun Dang PharmaceuticalLixiana
Rocheacenocoumarol

Clinical Trials (6)

Total enrollment: 470 patients across 6 trials

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration

Start: Jun 2023Est. completion: Sep 202368 patients
Phase 1Unknown

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration

Start: Jun 2023Est. completion: Sep 202368 patients
Phase 1Unknown

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers

Start: Apr 2021Est. completion: Jun 202160 patients
Phase 1Unknown

A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Start: Jan 2021Est. completion: Dec 202120 patients
Phase 1Unknown

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

Start: Nov 2020Est. completion: Jan 202150 patients
Phase 1Unknown
NCT03154489Rocheacenocoumarol

Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care

Start: May 2017Est. completion: Sep 2019204 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.